Impact of transjugular intrahepatic portosystemic shunt on post-colectomy complications in patients with ulcerative colitis and primary sclerosing cholangitis

Gursimran Kochhar¹, Udayakumar Navaneethan¹, Jose Mari Parungao¹, Jason Hartman², Ranjan Gupta¹, Rocio Lopez¹, Arthur J McCullough¹, Baljiendra Kapoor³ and Bo Shen¹

¹Department of Gastroenterology and Hepatology, The Cleveland Clinic, Cleveland, OH, USA, ²Case Western Reserve University School of Medicine, Cleveland, OH, USA and ³Department of Vascular and Interventional Radiology, The Cleveland Clinic, Cleveland, OH, USA

Abstract

Objective: Primary sclerosing cholangitis (PSC) occurs in approximately 5% of patients with ulcerative colitis (UC). The risk of colon cancer is higher in patients undergoing colectomy, who have simultaneous PSC & UC. Our aim was to study the impact, in terms of post-colectomy survival and complications, of transjugular intrahepatic portosystemic shunt (TIPS) before colectomy in these patients.

Methods: In this retrospective, case-control study, information was obtained on demographics, disease characteristics, TIPS characteristics, and post-colectomy complications. Nine patients with PSC and UC who underwent TIPS prior to colectomy (the Study group) and 37 patients with PSC and UC who underwent only colectomy without TIPS (the Control group) were included. Either an analysis of variance or the non-parametric Kruskal-Wallis test were used for continuous variables and Fisher’s Exact test or Pearson’s chi-squared test was used for categorical factors.

Results: There was no difference in the mean age between the two groups; however patients in the Study group had lower platelet count ($P = 0.005$) as well as higher Model for End-Stage Liver disease (MELD) scores ($P < 0.001$). Also, patients in the Study group had increased PSC severity as determined by Mayo PSC Risk Scores (1.50 vs. 0.20) ($P = 0.001$). Total bilirubin levels were higher in the Study group (2.3 vs. 0.8 mg/dL) ($P = 0.011$). Comparing the post-operative complication rates without adjusting for disease severity, the Study group had more wound infections ($P = 0.034$), more wound dehiscence ($P = 0.022$), and a higher re-admission rate within 30 days ($P = 0.032$); however, the post-operative mortality was not significantly different.

Conclusion: Patients with PSC and UC who underwent TIPS prior to colectomy had higher rates of complications; however, this was probably due to the greater severity of cirrhosis and PSC in this population.

Key words: primary sclerosing cholangitis; ulcerative colitis; transjugular intrahepatic portosystemic shunt (TIPS); colectomy
Introduction

Primary sclerosing cholangitis (PSC) is a rare, idiopathic disease with a prevalence of 13.6 per 100,000 persons [1]. It is characterized by inflammation, fibrosis, and strictures of the biliary tree [1–3]. PSC has long been reported as occurring in association with ulcerative colitis (UC) [4–6]. Studies have demonstrated that 44–90% of patients with PSC have underlying UC [1, 7, 8]; however, as few as 5% of patients with UC will simultaneously develop PSC [8]. Some writers have proposed that PSC coinciding with inflammatory bowel disease (IBD) may represent a unique phenotype of IBD, distinct from UC and Crohn’s disease [3, 9].

Patients with PSC often progress to cirrhosis [2]. While the definitive treatment is liver transplantation [3, 10, 11], patients may receive a transjugular intrahepatic portosystemic shunt (TIPS) to manage symptoms such as bleeding esophageal varices, parastomal varices and portal hypertension [12, 13]. Placement of TIPS has been shown to be a minimally invasive and effective means of controlling variceal bleeding, ascites and portal hypertension [12, 14–16].

Patients with PSC and UC also frequently undergo colectomy for the management of UC-related symptoms and complications [17]. Studies have also found that patients with PSC and UC are at high risk for colon cancer [18, 19]. In addition, colectomy has been demonstrated to be protective against recurrence of PSC following liver transplantation [20, 21].

In patients with UC who undergo colectomy, long-term quality of life is considered to be equivalent to that of the normal healthy population [22]; however common post-operative complications of patients with UC undergoing colectomy include wound infection, ileus, bleeding, and the formation of fistulae [23, 24]: major complication rates as high as 27% have been reported [25]. It has been suggested that placement of a TIPS prior to abdominal surgery in cirrhotic patients may improve surgical outcomes [26]; however, there are contradictory studies that found no difference in outcomes [27].

The aim of our study was to determine, in patients who underwent colectomy for the treatment of PSC associated with UC, whether TIPS prior to the colectomy altered their rates of post-operative complications.

Materials and methods

Data source

This is a retrospective chart review, approved by our hospital institutional review board (IRB). Data was collected from previously established data base, of all patients undergoing TIPS at our institution from period of 2001 to 2011. This data base was established retrospectively by our department of interventional radiology at Cleveland clinic and includes patient demographic information, indication of TIPS and procedure date.

Inclusion and exclusion criteria

Patients were included if they underwent colectomy after being diagnosed with PSC and UC at our institution from 2001 to 2011. This was determined using International Classification of Diseases 9th Revision (ICD-9) codes. Patients were excluded from the Study group if they underwent TIPS after colectomy. Patients who met the selection criteria were then divided into two groups: those who had undergone TIPS prior to colectomy (the Study group) and those not having undergone TIPS (the Control group).

Variables

Demographic information was obtained from the above-mentioned database, including age, gender, race, alcohol use, tobacco use, hepatitis B virus (HBV) and hepatitis C virus (HCV) status, family history of inflammatory bowel disease (IBD), and body mass index (BMI). Information on PSC and UC characteristics was obtained, including duration of PSC, the use of various medical therapies, albumin levels, total bilirubin levels, liver function tests [including aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], alkaline phosphatase (ALP), blood urea nitrogen (BUN), serum creatinine, hemoglobin, platelet counts, international normalized ratio (INR), activated partial thromboplastin time (APTT), and the model for end-stage liver disease score (MELD). The Mayo Risk Score system was used to evaluate the severity of PSC [28].

Information related to colectomy was obtained, including duration of UC at time of colectomy, the indication for colectomy, restoration, and type of ileostomy. Information related to TIPS was obtained, including time from TIPS to colectomy and clinical indication.

Outcomes of interest

Our primary outcome of interest was post-operative complications following colectomy and whether or not placement of TIPS affected these complications. Complications examined included hypotension, desaturation, bleeding requiring transfusions, re-admission within 30 days, reason for re-admission, ileus, obstruction, wound infection, wound dehiscence, abdominal abscess, pelvic abscess, deep vein thrombosis, proximal vein thrombosis, sepsis, peritonitis, anastomotic leakage, fistula, worsening liver function tests, coagulopathy, pulmonary complications, urinary complications, emergency re-operation, and mortality.

Statistical analysis

Univariate analysis was performed to assess differences between subjects with and without TIPS. Either analysis of variance or the non-parametric Kruskal-Wallis test were used for continuous variables, and Fisher’s exact test or Pearson’s chi-squared test was used for categorical factors. A P < 0.05 was considered statistically significant. SAS (version 9.2, The SAS Institute, Cary, NC) was used for all analyses. Data are presented as mean ± standard deviation, median (25th, 75th percentiles) or n (%).

Results

A total of 50 patients with PSC and UC underwent colectomy. Of these, 13 received a TIPS (the Study group), while 37 did not (the Control group). Four of the 13 TIPS were performed after colectomy and were therefore excluded, leaving 9 patients in the Study group (Figure 1).

Clinical characteristics

The Study group and the Control group did not significantly differ in terms of age, gender, race, smoking status, alcohol use, HBV status, HCV status, family history of IBD, BMI, or prevalence of obesity (Table 1).

There were a number of significant differences in PSC characteristics between the two groups (Table 2). Patients in the Study group had higher median Mayo Risk Scores (1.5) vs. the
Control group 

Values presented as Mean ± SD with ANOVA or n (%) with Fisher’s Exact test (F) or otherwise Pearson’s chi-squared test.

Partial data are not available in some cases.

TIPS = transjugular intrahepatic portosystemic shunt; IBD = inflammatory bowel disease.

Table 1. Characteristics of primary sclerosing cholangitis

| Factor                           | n* | No TIPS (n = 37) | TIPS (n = 9) | P-value |
|----------------------------------|----|-----------------|--------------|---------|
| Duration of PSC at colectomy (years) | 31 | 7.0 (2.0, 15.0) | 3.5 (2.0, 4.5) | 0.31    |
| Severity- Mayo Risk Score        | 40 | 0.20 (–0.64, 0.77) | 1.5 (0.85, 2.4) | 0.001   |
| Albumin (g/dL)                   | 40 | 3.8 ± 0.66       | 2.8 ± 0.55   | <0.001  |
| Total bilirubin (mg/dL)          | 40 | 0.80 (0.50, 1.3) | 2.3 (1.1, 4.8) | 0.011   |
| Aspartate aminotransferase (U/L) | 40 | 53.0 (27.0, 78.0) | 51.0 (36.0, 68.0) | 0.97    |
| Alanine aminotransferase (U/L)   | 39 | 49.5 (25.5, 83.5) | 41.0 (19.0, 118.0) | 0.71    |
| Alkaline phosphatase (U/L)       | 40 | 227 (123, 387)   | 410 (249, 497) | 0.29    |
| Blood urea nitrogen (mg/dL)      | 41 | 11.0 (10.0, 18.0) | 15.0 (12.0, 19.0) | 0.21    |
| Serum creatinine (mg/dL)         | 41 | 0.92 ± 0.34      | 0.78 ± 0.28  | 0.3     |
| Hemoglobin (g/dL)                | 41 | 12.7 ± 1.9       | 9.8 ± 0.90   | <0.001  |
| Platelets (×10^9/L)              | 40 | 329.4 ± 143.6    | 148.5 ± 95.6 | 0.005   |
| International normalized ratio   | 37 | 1.03 ± 0.25      | 1.3 ± 0.30   | 0.026   |
| Activated partial thromboplastin time(s) | 34 | 30.7 ± 3.5          | 35.1 ± 8.2          | 0.045   |
| MELD score                       | 37 | 8.2 ± 2.7        | 13.8 ± 5.0    | <0.001  |

Values presented as Mean ± SD with ANOVA; Median (P25, P75) with Kruskal-Wallis test.

Partial data are not available in some cases.

TIPS = transjugular intrahepatic portosystemic shunt; MELD = Model for end-stage liver disease.
based on a study of experiences with seven severely cirrhotic patients, three of whom underwent surgery of the colon [26]. However, other studies have disagreed with these findings. A retrospective examination of the effect of pre-surgery TIPS on patients with cirrhosis undergoing abdominal surgery found that pre-operative TIPS placement did not affect survival, nor did it cause significant differences in post-operative complications [27]. Their study population consisted of 10 patients undergoing colectomy, five undergoing antrectomy, one small-bowel resection, one pancreatectomy, and one nephrectomy.

### Table 3: Ulcerative colitis and colectomy characteristics

| Factor                                      | n* | No TIPS (n = 37) | TIPS (n = 9) | P-value |
|---------------------------------------------|----|-----------------|-------------|---------|
| Duration of UC at colectomy (years)         | 40 | 18.0 (13.0, 33.0) | 25.5 (15.0, 30.0) | 0.56    |
| Pre-colectomy treatment (non-exclusive)     | 31 |                 |             |         |
| Anti-inflammatory treatment                 | 18 | 66.7            | 4 (100.0)   | 0.30F   |
| Steroids                                    | 23 | (85.2)          | 3 (75.0)    | 0.52F   |
| Immunomodulators                            | 7  | (25.9)          | 2 (50.0)    | 0.56F   |
| Indication for colectomy (non-exclusive)    | 44 |                 |             |         |
| Refractory to medications                  | 13 | (35.1)          | 4 (57.1)    | 0.40F   |
| Dysplasia                                   | 19 | (51.4)          | 3 (42.9)    | 0.99F   |
| Carcinoma                                   | 3  | (8.1)           | 0 (0.0)     | 0.99F   |
| Adenomatous polyps                          | 2  | (5.4)           | 1 (14.3)    | 0.41F   |
| Restoration                                 | 44 | 35 (94.6)       | 3 (42.9)    | <0.001  |
| Type of restoration                         | 38 |                 |             | 0.99F   |
| IPAA                                        | 33 | (94.3)          | 3 (100.0)   |         |
| Ileorectal                                  | 2  | (5.7)           | 0 (0.0)     |         |
| Ileostomy                                   | 45 | 35 (94.6)       | 8 (100.0)   | 0.99F   |
| Type of ileostomy                           | 42 |                 |             | <0.001  |
| Loop                                        | 33 | (94.3)          | 3 (42.9)    |         |
| End                                         | 2  | (5.7)           | 4 (57.1)    |         |
| Post-operative complications                | 46 | 37 (100.0)      | 8 (88.9)    | 0.20F   |
| Bleeding                                    | 44 | 6 (16.2)        | 1 (14.3)    | 0.9     |
| Ileus                                       | 44 | 8 (21.6)        | 1 (14.3)    | 0.56F   |
| Obstruction                                 | 44 | 2 (5.4)         | 0 (0.0)     | 0.99F   |
| Wound infection                             | 44 | 4 (10.8)        | 3 (42.9)    | 0.034   |
| Wound dehiscence                            | 44 | 0 (0.0)         | 2 (28.6)    | 0.022F  |
| Abdominal abscess                           | 44 | 2 (5.4)         | 2 (28.6)    | 0.11F   |
| Pelvic abscess                              | 44 | 6 (16.2)        | 1 (14.3)    | 0.9     |
| Deep venous thrombosis                      | 44 | 0 (0.0)         | 0 (0.0)     | 0.99F   |
| Portal vein thrombosis                      | 46 | 1 (2.7)         | 0 (0.0)     | 0.99F   |
| Septicemia                                  | 44 | 2 (5.4)         | 1 (14.3)    | 0.41F   |
| Peritonitis                                 | 44 | 0 (0.0)         | 0 (0.0)     | 0.99F   |
| Anastomotic leak                            | 44 | 4 (10.8)        | 1 (14.3)    | 0.99F   |
| Fistula                                     | 44 | 0 (0.0)         | 1 (14.3)    | 0.16F   |
| Worsening liver function tests              | 44 | 2 (5.4)         | 0 (0.0)     | 0.99F   |
| Coagulopathy                                | 44 | 1 (2.7)         | 0 (0.0)     | 0.99F   |
| Pulmonary complications                     | 44 | 0 (0.0)         | 1 (14.3)    | 0.16F   |
| Urinary complications                       | 44 | 1 (2.7)         | 0 (0.0)     | 0.99F   |
| Other complication                          | 37 | 1 (2.7)         | 0 (0.0)     | 0.99F   |
| Blood transfusions requested                | 42 | 1 (2.8)         | 2 (33.3)    | 0.049F  |
| No. of blood transfusion                    | 38 |                 |             | 0.001   |
| 0                                           | 33 | (94.3)          | 1 (33.3)    |         |
| 1                                           | 1  | (2.9)           | 1 (33.3)    |         |
| 4                                           | 0  | (0.0)           | 1 (33.3)    |         |
| 5                                           | 1  | (2.9)           | 0 (0.0)     |         |
| Hospital stay (days)                        | 44 | 5.0 (5.0, 8.0)  | 8.0 (7.0, 23.0) | 0.041 |
| Re-admission within 30 days                 | 44 | 7 (18.9)        | 4 (57.1)    | 0.032   |
| Reason for re-admission (non-exclusive)     | 11 |                 |             |         |
| Nausea/vomiting                             | 0  | (0.0)           | 1 (25.0)    | 0.36F   |
| Renal failure                               | 1  | (14.3)          | 0 (0.0)     | 0.99F   |
| Infection                                   | 4  | (57.1)          | 3 (75.0)    | 0.99F   |
| Wound dehiscence                            | 1  | (14.3)          | 0 (0.0)     | 0.99F   |
| Bowel obstruction                           | 1  | (14.3)          | 0 (0.0)     | 0.99F   |
| Emergency re-operation                      | 45 | 2 (5.4)         | 0 (0.0)     | 0.99F   |
| Post-operative mortality                    | 46 | 0 (0.0)         | 1 (11.1)    | 0.20F   |

Values presented as Median [P25, P75] with Kruskal-Wallis test, or n (%) with Fisher’s Exact test (F) or otherwise Pearson’s chi-squared test.

*Partial data are not available in some cases.

TIPS = transjugular intrahepatic portosystemic shunt; IPAA = ideal pouch-anal anastomosis
while, in the control population of 18 patients, 13 underwent colectomy [26].

These earlier studies led us to hypothesize that TIPS placement prior to colectomy might at best improve outcomes, or at worst offer no significant benefit. It was therefore unexpected that placement of a TIPS was associated with increased intra-operative and post-operative complications.

Our findings suggest that the cause was not the presence of TIPS, but rather that patients in the Study group had more severe cirrhosis, which made both TIPS placement and post-colectomy complications more likely. This agrees with the PSC characteristics of the Study group described above, such as increased Mayo Risk Score, decreased serum albumin, increased total bilirubin, increased INR, increased APTT, and increased MELD score, all of which suggest more severe cirrhosis. This suggests that patients with severe disease, who undergo TIPS, are still at risk of worse outcomes than patients with mild disease, irrespective of the presence or absence of TIPS.

The increased INR and APTT explain the increased intra-operative bleeding requiring blood transfusions. The increased rate of wound infections seen in the Study group may also be the result of more severe cirrhosis. Various studies have shown that patients with cirrhosis are likely to acquire secondary infections while hospitalized [29, 30]; it is thought that patients with cirrhosis have impaired immune function [31]. Studies have also suggested that patients with cirrhosis produce less glutathione, which increases their risk of infection [32, 33]. It is also possible that those in the Study group were taking higher doses of immunomodulators; this could not be ascertained, as we only looked at use of immunomodulators as a categorical variable.

Wound infection has been shown to be a major risk factor in the development of wound dehiscence following abdominal surgery, through the increased presence of neutrophils and matrix metalloproteinases [34]. This may explain the increased rate of wound dehiscence observed in our Study group. The higher rates of wound infection and dehiscence offer an explanation for the increased re-admissions within 30 days.

This study is limited by its retrospective nature and the use of databases, which may have introduced further confounding factors such as incorrect coding. We were also limited by the fact that we were examining a rare disease: out of our entire database, we were only able to find nine patients to include in the Study group, which may not have been large enough to provide sufficient power to detect all complications. Data on liver transplantation and dosing regimens of immunosuppressive medications might have been useful but were not available. In addition, this is a single-institutional study, which limits the general applicability of our findings.

In conclusion, our findings suggest that patients who underwent TIPS placement had more severe cirrhosis, which led to an increase in intra-operative and post-operative complications. But what remains unclear is whether TIPS placement may have exacerbated or diminished these complications. Based on our initial findings, prospective tracking of patients with PSC and UC undergoing colectomy following TIPS may be warranted.

Conflict of interest statement: none declared.

References
1. Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364–9.
2. Wiesner RH, Grambsch PM, Dickson ER et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989;10:430–6.
3. Karlsen TH and Boberg KM. Update on primary sclerosing cholangitis. J Hepatol 2013;59:571–82.
4. Atkinson AJ and Carroll WW. Sclerosing cholangitis. Association with regional enteritis. JAMA 1964;188:183–4.
5. Schaeffer DF, Win LL, Hafezi-Bakhtiari S et al. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig Dis Sci 2013;58:2608–14.
6. Smith MF and Loe RH. Sclerosing cholangitis: review of recent case reports and associated diseases and four new cases. Am J Surg 1965;110:239–46.
7. Escorsell A, Pares A, Rodes J et al. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994;21:787–91.
8. Tung BY, Brentnall T, Kowdley KV et al. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (abstract). Hepatology 1996;24:169A.
9. Loftus EV Jr., Harwood GC, Loftus CG et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;4:91–6.
10. Langnas AN, Grazi GL, Stratta RJ et al. Primary sclerosing cholangitis: the emerging role for liver transplantation. Am J Gastroenterol 1990;85:1316–41.
11. McEntee G, Wiesner RH, Rosen C et al. A comparative study of patients undergoing liver transplantation for primary sclerosing cholangitis and primary biliary cirrhosis. Transplant Proc 1991;23:1563–4.
12. Pennick MO and Artioukh DY. Management of parastomal varices: who re-bleeds and who does not? A systematic review of the literature. Tech Coloproctol 2013;17:63–70.
13. Kawamata H, Kumazaki T, Kanazawa H et al. Transjugular intrahepatic portosystemic shunt in a patient with cavernomatous portal vein occlusion. Cardiovasc Intervent Radiol 2000;23:145–9.
14. Burroughs AK and Vangeli M. Transjugular intrahepatic portosystemic shunt vs. endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol 2002;37:249–52.
15. Galant F, Camma C, Enea M et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825–34.
16. Garcia-Tsao G. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites. Nat Clin Pract Gastroenterol Hepatol 2006;3:380–9.
17. Cima RR and Pemberton JH. Medical and surgical management of chronic ulcerative colitis. Arch Surg 2005;140:300–10.
18. Venkatesh PG, Jegadeesan R, Gutierrez NG et al. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis 2013;7:968–73.
19. Knechtle SJ, D’Alessandro AM, Harms BA et al. Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery 1995;118:615–20.
20. Vera A, Moledina S, Gunson B et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360:1943–4.
21. Alabraba E, Nightingale P, Gunson B et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. *Liver Transpl* 2009;15:330–40.

22. Heikens JT, de Vries J and van Laarhoven CJ. Quality of life, health-related quality of life and health status in patients having restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review. *Colorectal Dis* 2012;14:536–44.

23. Marcello PW, Milsom JW, Wong SK et al. Laparoscopic total colectomy for acute colitis: a case-control study. *Dis Colon Rectum* 2001;44:1441–5.

24. Marceau C, Alves A, Ouaisi M et al. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. *Surgery* 2007;141:640–4.

25. Coakley BA, Telem D, Nguyen S et al. Prolonged pre-operative hospitalization correlates with worse outcomes after colectomy for acute fulminant ulcerative colitis. *Surgery* 2013;153:242–8.

26. Azoulay D, Buabse F, Damiano I et al. Neoadjuvant transjugular intrahepatic portosystemic shunt: a solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension. *J Am Coll Surg* 2001;193:46–51.

27. Vinet E, Perreault P, Bouchard L et al. Transjugular intrahepatic portosystemic shunt before abdominal surgery in cirrhotic patients: a retrospective, comparative study. *Can J Gastroenterol* 2006;20:401–4.

28. Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis. *Mayo Clin Proc* 2000;75:688–94.

29. Bajaj JS, O’Leary JG, Reddy KR et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. *Hepatology* 2012;56:2328–35.

30. Park HJ, Lee YM, Bang KM et al. Clinical significance of Staphylococcus aureus bacteremia in patients with liver cirrhosis. *Eur J Clin Microbiol Infect Dis* 2012;31:3309–16.

31. Taneja SK and Dhiman RK. Prevention and management of bacterial infections in cirrhosis. *Int J Hepatol* 2011;2011:784540.

32. Czeczot H, Scibior D, Skrzycki M et al. Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. *Acta Biochim Pol* 2006;53:237–42.

33. Morris D, Khurasany M, Nguyen T et al. Glutathione and infection. *Biochim Biophys Acta* 2013;1830:3329–49.

34. van Ramshorst GH, Nieuwenhuizen J, Hop WC et al. Abdominal wound dehiscence in adults: development and validation of a risk model. *World J Surg* 2010;34:20–7.